Psychiatric News (2/20) reported a study found that “the cannabis derivative cannabinol (CBN) reduced the time needed to fall asleep in a small sample of individuals with insomnia but didn’t significantly reduce time spent awake after initial sleep onset.” Researchers observed that for study participants with a diagnosed insomnia disorder, “CBN 300mg and 30mg reduced wake after sleep onset by six and four minutes, respectively, but researchers said neither change was statistically or clinically significant. CBN 300mg halved average sleep onset time from 14 minutes to seven – a meaningful reduction similar to those reported in studies of melatonin or prescription sleep aids.” Furthermore, they noted that “CBN 300mg also increased time spent in N2 sleep (the transition from light sleep to deep sleep) and increased participants’ subjective sleep quality.” The study was published in the Journal of Sleep Research.
Related Links:
— “Cannabinol Fails to Reduce Nighttime Waking but Provides Other Sleep Benefits, Psychiatric News, February 20, 2026